Table 1.
CR group | Advanced group | P value | |
---|---|---|---|
No. patients | 32 | 31 | |
Median age, years (range) | 37 (15–52) | 41 (19–62) | P = 0.24 |
Sex | P = 0.32 | ||
Male | 18 | 13 | |
Female | 14 | 18 | |
Diagnosis | P = 0.479 | ||
De novo AML | 31 | 28 | |
Secondary AML | 1 | 2 | |
MDS-AML | 0 | 1 | |
Risk classification at diagnosis* | P = 0.001 | ||
High | 11 | 24 | |
Intermediate | 21 | 7 | |
Median interval from diagnosis to HSCT, months (range) | 8 (3–19) | 8 (3–68) | P = 0.096 |
Tapering of immunosuppressive agents | |||
Early | 7 | 22 | P < 0.001 |
Regular | 25 | 9 | |
Disease status at transplantation | |||
CR1 | 25 | ||
CR2 | 7 | ||
Secondary refractory | 23 | ||
Primary refractory | 8 | ||
Donor characteristics | P = 0.556 | ||
Matched related (10/10) | 15 | 14 | |
Matched unrelated (10/10) | 10 | 12 | |
Matched unrelated (9/10) | 7 | 5 | |
Conditioning regimens | P = 0.359 | ||
BFAT | 18 | 15 | |
BCAT | 14 | 16 |
CR complete remission, AML acute myeloid leukemia, MDS-AML myelodysplastic syndrome-related acute myeloid leukemia, BFAT busulfan+fludarabine+Ara-C+TBI, BCAT busulfan+cladribine+Ara-C+TBI
*Risk classification at diagnosis was evaluated according to the cytogenetics at the time of diagnosis [21]